Cargando…

Integrating pharmacokinetics and network analysis to investigate the mechanism of Moutan Cortex in blood-heat and blood stasis syndrome

BACKGROUND: Raw Moutan Cortex (RMC) has been used in China and other Asian countries for thousands of years. Its medical application is the treatment of cooling blood and promoting blood circulation. However, its therapeutic mechanism is still undefined. METHODS: In this study, the pharmacokinetics...

Descripción completa

Detalles Bibliográficos
Autores principales: Ye, Qiuli, Zhang, Ying, Yan, Donghui, Sun, Yue, Li, Ming, Cao, Hui, Wang, Shumei, Meng, Jiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9476706/
https://www.ncbi.nlm.nih.gov/pubmed/36104759
http://dx.doi.org/10.1186/s13020-022-00657-w
_version_ 1784790197577187328
author Ye, Qiuli
Zhang, Ying
Yan, Donghui
Sun, Yue
Li, Ming
Cao, Hui
Wang, Shumei
Meng, Jiang
author_facet Ye, Qiuli
Zhang, Ying
Yan, Donghui
Sun, Yue
Li, Ming
Cao, Hui
Wang, Shumei
Meng, Jiang
author_sort Ye, Qiuli
collection PubMed
description BACKGROUND: Raw Moutan Cortex (RMC) has been used in China and other Asian countries for thousands of years. Its medical application is the treatment of cooling blood and promoting blood circulation. However, its therapeutic mechanism is still undefined. METHODS: In this study, the pharmacokinetics strategy that integrated network analysis was employed to explore the mechanism of RMC in blood-heat and blood stasis syndrome (BHS) model rats. Firstly, Ultra-High performance Liquid Chromatography coupled with Diode Array Detector (UHPLC-DAD) method was developed to determine nine absorbed compounds in rat serum in BHS and normal rats after oral administration of RMC extract respectively. Then the pharmacology network was established based on the relationship between nine compounds absorbed into the blood and BHS targets. Finally, the predicted hub targets were validated experimentally in human umbilical vein endothelial cells (HUVECs). RESULTS: Pharmacokinetic study showed that the pharmacokinetic parameters of nine absorbed compounds had significant differences between BHS and normal groups (p < 0.05). Network analysis showed that 8 target genes, namely, F2, F10, F7, PLAU, MAPK14, MAPK10, AKT1, and NOS3 may be the primary targets regulated by RMC for the treatment of BHS. Among them, targets (F2, F10, F7 and MAPK14, MAPK10, AKT) and 4 active ingredients (paeonol, paeoniflorin, quercetin and oxypaeoniflorin) were selected for evaluating the reliability in vitro experiments, which revealed that the mechanism of RMC against BHS syndrome may inhibit inflammatory pathways and regulate coagulation cascades pathway for cooling and promoting blood circulation. CONCLUSION: The proposed pharmacokinetics study integrated network analysis strategy provides a combination method to explore the therapeutic mechanism of RMC on BHS. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13020-022-00657-w.
format Online
Article
Text
id pubmed-9476706
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-94767062022-09-16 Integrating pharmacokinetics and network analysis to investigate the mechanism of Moutan Cortex in blood-heat and blood stasis syndrome Ye, Qiuli Zhang, Ying Yan, Donghui Sun, Yue Li, Ming Cao, Hui Wang, Shumei Meng, Jiang Chin Med Research BACKGROUND: Raw Moutan Cortex (RMC) has been used in China and other Asian countries for thousands of years. Its medical application is the treatment of cooling blood and promoting blood circulation. However, its therapeutic mechanism is still undefined. METHODS: In this study, the pharmacokinetics strategy that integrated network analysis was employed to explore the mechanism of RMC in blood-heat and blood stasis syndrome (BHS) model rats. Firstly, Ultra-High performance Liquid Chromatography coupled with Diode Array Detector (UHPLC-DAD) method was developed to determine nine absorbed compounds in rat serum in BHS and normal rats after oral administration of RMC extract respectively. Then the pharmacology network was established based on the relationship between nine compounds absorbed into the blood and BHS targets. Finally, the predicted hub targets were validated experimentally in human umbilical vein endothelial cells (HUVECs). RESULTS: Pharmacokinetic study showed that the pharmacokinetic parameters of nine absorbed compounds had significant differences between BHS and normal groups (p < 0.05). Network analysis showed that 8 target genes, namely, F2, F10, F7, PLAU, MAPK14, MAPK10, AKT1, and NOS3 may be the primary targets regulated by RMC for the treatment of BHS. Among them, targets (F2, F10, F7 and MAPK14, MAPK10, AKT) and 4 active ingredients (paeonol, paeoniflorin, quercetin and oxypaeoniflorin) were selected for evaluating the reliability in vitro experiments, which revealed that the mechanism of RMC against BHS syndrome may inhibit inflammatory pathways and regulate coagulation cascades pathway for cooling and promoting blood circulation. CONCLUSION: The proposed pharmacokinetics study integrated network analysis strategy provides a combination method to explore the therapeutic mechanism of RMC on BHS. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13020-022-00657-w. BioMed Central 2022-09-14 /pmc/articles/PMC9476706/ /pubmed/36104759 http://dx.doi.org/10.1186/s13020-022-00657-w Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Ye, Qiuli
Zhang, Ying
Yan, Donghui
Sun, Yue
Li, Ming
Cao, Hui
Wang, Shumei
Meng, Jiang
Integrating pharmacokinetics and network analysis to investigate the mechanism of Moutan Cortex in blood-heat and blood stasis syndrome
title Integrating pharmacokinetics and network analysis to investigate the mechanism of Moutan Cortex in blood-heat and blood stasis syndrome
title_full Integrating pharmacokinetics and network analysis to investigate the mechanism of Moutan Cortex in blood-heat and blood stasis syndrome
title_fullStr Integrating pharmacokinetics and network analysis to investigate the mechanism of Moutan Cortex in blood-heat and blood stasis syndrome
title_full_unstemmed Integrating pharmacokinetics and network analysis to investigate the mechanism of Moutan Cortex in blood-heat and blood stasis syndrome
title_short Integrating pharmacokinetics and network analysis to investigate the mechanism of Moutan Cortex in blood-heat and blood stasis syndrome
title_sort integrating pharmacokinetics and network analysis to investigate the mechanism of moutan cortex in blood-heat and blood stasis syndrome
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9476706/
https://www.ncbi.nlm.nih.gov/pubmed/36104759
http://dx.doi.org/10.1186/s13020-022-00657-w
work_keys_str_mv AT yeqiuli integratingpharmacokineticsandnetworkanalysistoinvestigatethemechanismofmoutancortexinbloodheatandbloodstasissyndrome
AT zhangying integratingpharmacokineticsandnetworkanalysistoinvestigatethemechanismofmoutancortexinbloodheatandbloodstasissyndrome
AT yandonghui integratingpharmacokineticsandnetworkanalysistoinvestigatethemechanismofmoutancortexinbloodheatandbloodstasissyndrome
AT sunyue integratingpharmacokineticsandnetworkanalysistoinvestigatethemechanismofmoutancortexinbloodheatandbloodstasissyndrome
AT liming integratingpharmacokineticsandnetworkanalysistoinvestigatethemechanismofmoutancortexinbloodheatandbloodstasissyndrome
AT caohui integratingpharmacokineticsandnetworkanalysistoinvestigatethemechanismofmoutancortexinbloodheatandbloodstasissyndrome
AT wangshumei integratingpharmacokineticsandnetworkanalysistoinvestigatethemechanismofmoutancortexinbloodheatandbloodstasissyndrome
AT mengjiang integratingpharmacokineticsandnetworkanalysistoinvestigatethemechanismofmoutancortexinbloodheatandbloodstasissyndrome